Table III.
Implementation of pathogen reduction technologies by EU Member State and Switzerland in 2018.
| Country | PR of plasma (% of use) | PR of PLTs (% of use) | Country | PR of plasma (% of use) | PR of PLTs (% of use) |
|---|---|---|---|---|---|
| Belgium | u | u | Slovenia | 0 | p (98%) |
| Iceland | u | u | Croatia | 0 | e |
| France | p (10%–20%) | u | Latvia | 0 | 0 |
| Switzerland | p (30%) | u | Denmark | 0 | 0 |
| Norway | u | p (7%) | Malta | 0 | 0 |
| Luxembourg | 0 | u | Netherlands | u | 0 |
| Germany | p (n.a.) | p (n.a.) | Estonia | 0 | 0 |
| Greece | p (n.a.) | p (n.a.) | Finland | u | 0 |
| Austria | p (65%) | p (35%) | Bulgaria | 0 | 0 |
| Italy | p (48%) | p (6%) | United Kingdom | 0 | 0 |
| Poland | p (n.a.) | p (n.a.) | Hungary | 0 | 0 |
| Portugal (Lisbon Centre) | p (~ 5%) | p (~24.%) | Ireland | 0 | 0 |
| Spain | p (31%) | p (37%) | Cyprus | 0 | 0 |
| Sweden | p (17%) | p (52%) | Slovakia | e | e |
| Czech Republic | 0 | p (1%) | Romania | 0 | 0 |
| Lithuania | 0 | p (1%) | Liechtenstein | n.a. | n.a. |
PR: pathogen reduction; PLTs : platelets; 0: not implemented; u: universal implementation; p: partial implementation; e: experimental use; n.a.: data not available.